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Abstract. We have evaluated the potential usefulness of 
indium-111 labelled [DTPA-D-Phel]RC-160, derived 
from the octapeptide somatostatin a alogue RC-160, as 
a radiopharmaceutical for the in vivo detection of soma- 
tostatin receptor-positive tumours. For this purpose 111In- 
and 11Sin-labelled [DTPA-D-Phe~]RC-160 was tested for 
its biological activity, and applied for somatostatin re- 
ceptor scintigraphy in vivo to rats bearing the transplant- 
able rat pancreatic tumour CA20948, which expresses 
somatostatin receptors. We previously described the de- 
velopment of the 1HIn-labelled somatostatin analogue 
[DTPA-D-Phe~]octreotide and its use in the in vivo visu- 
alization of somatostatin receptor-positive tumours in 
rats and in humans. Like [mIn-DTPA-D-Phe~]octreotide, 
[mIn-DTPA-D-Phe~]RC-160 showed uptake in and spe- 
cific binding in vivo to somatostatin receptor-positive or-
gans and turnouts, and the tumours were clearly visual- 
ized by gamma camera scintigraphy. However, as com- 
pared to [1JlIn-DTPA-D-Phe~]octreotide, blood radioac- 
tivity (background) was higher, resulting in a lower tu- 
mour to blood (background) ratio. Using this animal 
model we therefore conclude that [U1In-DTPA-D- 
Phel]RC-160 has no advantage over [lllIn-DTPA-D- 
Phel]octreotide as a radiopharmaceutical n the visuali- 
zation of somatostatin receptors which bind both ana- 
logues. However, recent reports uggest the existence of 
different somatostatin receptor subtypes on some human 
cancers, which differentially bind RC-160 and not octre- 
otide. These turnouts include cancers of the breast, ovar- 
y, exocrine pancreas, prostate and colon. [H1In-DTPA-D- 
Phel]RC-160 might be of interest for future use in such 
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cancer patients as a radiopharmaceutical for imaging 
somatostatin receptor-positive turnouts, which do not 
bind octreotide. 
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I n t roduct ion  
High numbers of high-affinity somatostatin receptors for 
both native somatostatin (for structures, ee Fig. 1) and 
the synthetic octapeptide octreotide (Sandostatin), have 
been detected on most neuro-endocrine tumours, like en- 
docrine pancreatic tumours and carcinoids [1-4]. We, 
and also others, have recently described the visualization 
of somatostatin receptor-positive tumours in vivo after 
the intravenous administration of [123I-Tyr3]octreotide 
[5-12] and [UlIn-DTPA-D-Phel]octreotide [13-20]. Sev- 
eral reports have also been published on the in vitro 
binding to somatostatin receptors of another somatosta- 
tin analogue, the octapeptide RC-160 [21-23]. It has be- 
en reported that RC-160 has a higher affinity than octre- 
otide for somatostatin receptors in human breast, ovari- 
an, exocrine pancreatic, prostatic and colonic cancers 
[21-23]. A phase 1 clinical trial with RC-160 in patients 
with advanced exocrine pancreatic ancer suggests that 
RC-160 is well tolerated at doses up to 1500 ~tg/day 
[24-25]. The possibility of RC-160 binding to a soma- 
tostatin receptor subtype, which does not bind octreo- 
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Somatosta t in  
I I 
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys 
Octreotide 
I 1 
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol) 
Tyr3-octreotide 
I 1 
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol) 
[mln-DTPA-D-PheJ]octreotide 
I I 
mln-DTPA-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol) 
RC-160 
I I 
D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 
[mIn-DTPA-D-Phe ~] RC- 160 
I 1 
mln-DTPA-D-Phe-Cys-Tyr-D-Trp-Lys-VaI-Cys-Trp-NH2 
Fig. 1. Structural formulae of native somatostatin, octreotide, 
Tyr3-octreotide, [mln-DTPA-D-Phe~]octreotide, RC-160 and 
[l IIIn-DTPA-D-Phel]RC - 160 
tide, for example on human exocrine pancreatic adeno- 
carcinomas [26], offers a potential advantage of RC-160 
over octreotide as radio label led tumour tracer. Further- 
more, RC-160 and radio iodinated RC-160 may, in con- 
trast to octreotide [27], also pass the blood-brain barrier 
[28-30]. This could represent a benefit in visual iz ing 
somatostat in receptor-posit ive brain tumours with an in- 
tact b lood-brain barrier. We recently reported [30] our 
results with tumour visual izat ion with ~23I-RC-160 in tu- 
mour-bear ing rats and concluded that, despite the fact 
that 123I-RC-160 shows high-aff inity binding to various 
somatostat in receptor-posit ive tissues and tumours, no 
advantage over [123I-Tyr3]octreotide has been found in 
binding to the somatostat in receptor-posit ive tissues and 
tumours studied so far. Therefore, we compared [H~In- 
DTPA-D-Phel ]RC-160 with [Hl In-DTPA-D-Phel]octreo-  
tide (for structure see Fig. 1), as radiopharmaceut icals  
for scint igraphy in normal  rats and in rats bearing the 
transplantable pancreat ic somatostat in receptor-posit ive 
tumour CA20948 [26, 31, 32]. 
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Materials and methods 
Preparation and purification of the radiopharmaceuticals. RC- 
160 and [DTPA-D-Phe~]RC-160 were purchased from Sanbio 
(Uden, The Netherlands). [DTPA-D-Phe~]octreotide and ~lInC13 
(DRN 4901) were obtained from Mallinckrodt (Petten, The Neth- 
erlands). The radiolabelling of [DTPA-D-Phe~]octreotide and 
[DTPA-D-Phe~]RC-160 with HJIn and consecutive quality control 
were performed as described previously [33]. Although it is not 
excluded that additional groups of the peptides participate in 11 ~In 
complexation, the labelled products are referred to as [~ ~In-DT- 
PA-D-Phez]RC - 160 and [l~ iin_DTPA_D_Phe~ ]octreotide. The radi- 
ochemical purity of the radiolabelled somatostatin a alogues was 
greater than 95 %. All chemicals used were of the highest purity 
available. 
Animals and tumours. Male Lewis rats (240-260 g) were inoculat- 
ed in both upper hind legs with the transplantable rat pancreatic 
tumour CA20948, wich has previously been shown to possess 
somatostatin receptors [26]. Mate Lewis rats (240-260 g) not 
bearing the CA20948 tumour were used as control rats. 
For injection and scintigraphy the rats were anaesthetized with 
ether. 
In order to study specific binding, the rats were injected subcu- 
taneously with 1 mg RC-160 or l mg octreotide in 1 ml 0.05 M 
acetic acid containing 154 mM NaC1 or solvent. Forty-five min- 
utes later the rats were injected with either [H*In-DTPA-D- 
Phel]RC-160 or [mIn-DTPA-D-Phea]octreotide. Specific binding 
was defined as the difference between the tissue uptake in tumour- 
inoculated rats and that in similar animals treated with excess of 
unlabelled peptide, expressed as percentages of the injected radio- 
activity per gram tissue (mean _+ SD). 
The tracer agents were injected into the dorsal vein of the pe- 
nis. The dose was 18.5 MBq (0.5 ~g) for both analogues, meas- 
ured in a dose calibrator (VDC-202, Veenstra, Joure, The Nether- 
lands). The rats were sacrificed 2, 4, 24, 48 or 72 h after adminis- 
tration of the radiolabelled somatostatin a alogue. The concentra- 
tion of radioactivity in various tissues, urine and blood was subse- 
quently measured. [~HIn-DTPA-D-Phe~]octreotide and [ll~in_DT_ 
PA-D-PheJ]RC-160 binds to SEP-PAK C~8 stationary phase and is, 
using the separation technique as described by Bakker [6], only 
eluted with ethanol, while mIn-DTPA does not retain on SEP- 
PAK C~8 columns. Radioactivity in plasma and urine samples 
which is also eluted with ethanol from the SEP-PAK C~s column 
is termed peptide-bound radioactivity, but is not further character- 
ized. 
The radioactivity in blood and urine was analysed as described 
previously [6]. 
Biological activity and radioligand binding studies. [In-DTPA-D- 
Phe~]octreotide (labelled with natural indium, i.e. a mixture of 
4.23% non-radioactive ll3In and 95.77% IlsIn, 7"i/2=6.10 TM years, 
hereafter eferred to as HSIn) and [HSIn-DTPA-D-Phel]RC-160 
were prepared by mixing the respective [DTPA-D-Phe~]-soma - 
tostatin analogues (stock concentration of 10 -4 M) with 10 -3 M 
~lSInC13 (Aldrich) in 0.05 M acetic acid, to an 80-fold molar ex- 
cess ratio of indium over peptide. The biological activity of [DT- 
PA-D-Phe~]octreotide, [~5In-DTPA-D-Phe~]octreotide, [DTPA-D- 
Phe~]RC-160 and [HSIn-DTPA-D-Phe~]RC-160 was assessed by 
measuring potency to inhibit the secretion of rat growth hormone 
from cultured rat pituitary cells. The preparation of dispersed fe- 
male rat anterior pituitary cells and cell culture conditions have 
been described previously [34]. Receptor binding assays were car- 
ried out using [~2SI-Tyr3]octreotide as described previously [35]. 
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Binding curves and IC50 for displacement of [mSI-Tyr3]octreotide 
binding by unlabelled peptide were calculated from two experi- 
ments (triplicate determinations) using the computer fitting pro- 
gram of Graphpad (ISI software, Philadelphia, Pa., USA). 
Data acquisition and analysis. All results are expressed as the me- 
an + SD. One-way analysis of variance (ANOVA), was used for 
statistical analysis. For the comparison of means the Newman- 
Keuls or Bonfen-oni t-test was applied [36]. A P value of <0.05 
was considered significant. The tissue distribution and metabolism 
of the '~XIn-labelled somatostatin analogues in vivo were studied 
by gamma camera scintigraphy (Rota-II, Siemens) [13] and meas- 
urement of rain in isolated organs was performed using an LKB- 
1282-Compugammasystem. 
The ratio of tissue-binding values of tissue over soft tissue 
(thigh) and the radioactivity concentration ratio of tumour over 
soft tissue were calculated for each individual organ and for the 
tumours. 
Results 
Quality control, radiolabeIling and preparation 
of the radiopharmaceutical 
Amino acid analysis of RC-160 and [mIn-DTPA-D- 
Phe~]RC-160 yielded a peptide content of more than 
95% of the correct amino acid composition. The identity 
of the peptides was confirmed by last atom bombard- 
ment mass spectrometry, showing a molecular weight of 
1131 and 1507 daltons for RC-160 and [DTPA-D- 
Phel]RC -160, respectively. 
More than 95% efficiency of labelling, tested by in- 
stant thin-layer chromatography and confirmed by high- 
performance liquid chromatography, was assured when a 
molar excess of five- to tenfold of peptide over rain was 
used, resulting in the formation of [HIIn-DTPA-D- 
Phe~]RC-160 with a specific activity of 150 MBq lmIn 
per ~g [DTPA-D-Phel]RC-160. The [mIn-DTPA-D- 
Phel]RC -160 was stable for at least 4 h after preparation, 
and for longer than 24 h if stabilized by either dilution, 
with for instance saline, or addition of a quencher, such 
as gentisic acid. 
Receptor binding studies and biological activity 
Figure 2 shows binding of [125I-Tyr3]octreotide to rat 
brain cortex membranes in the presence of increasing 
concentrations of unlabelled [DTPA-D-Phe~]octreotide 
or [DTPA-D-Phel]RC - 160, with ICs0 values of 20 and 30 
nM, respectively. In Fig. 3 the effects of [I~5In-DTPA-D- 
Phe~]octreotide, [DTPA-D-Phel]octreotide, [I~SIn-DTPA- 
D-Phe~]RC-160 and [DTPA-D-Phel]RC-160 on the se- 
cretion of rat growth hormone by cultured rat anterior 
pituitary cells are shown. There was a dose-dependent 
inhibition of basal rat growth hormone release by these 
cells, with ICs0 values of 3, 8, 5 and 15 nM, respectively, 
for the four aforementioned compounds. There were no 
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Fig. 2. Binding of [~2SI-Tyr3]octreotide to rat brain cortex mem- 
branes in the presence of increasing concentrations of [DTPA-D- 
Phel]RC-160 (*) and [DTPA-D-Phel]octreotide (o),expressed as 
the percentage of binding in the absence of competing compounds 
(n=3, maximal SD < 10%). No significant differences were found 
at equimolar concentrations 
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Fig. 3. Effects of [I~5In-DTPA-D-Phel]RC-160 (11), [DTPA-D- 
Phel]RC-160(*), [~SIn-DTPA-D-Phe~]octreotide ([Z) and [DTPA- 
D-Phe~]octreotide (o) on the secretion of rat growth hormone 
(GH) from cultured rat pituitary cells (n--4, maximal SD < 15%). 
No significant differences were found at equimolar concentrations 
significant differences between the effects of the two 
l~SIn-labelled and the two non-labelled somatostatin ana- 
logues (P > 0.05, Student's t-test). Trivalent indium ions, 
up to a concentration of 8 - 10 .5 M, did not influence rat 
growth hormone assay (data not shown). 
Tissue distribution and specific binding 
The radioactivities measured in the isolated tumour and 
111 1 organs 24 h after injection of [ In-DTPA-D-Phe ]octre- 
otide and 24, 48 and 72 h after injection of [IllIn-DTPA- 
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Table 1. Tissue distribution (% injected 
dose per gram tissue, mean _+ SD) and 
tissue ratios in tumour-bearing rats (n _> 4) 
at indicated time intervals after intravenous 
administration of0.5 ~tg of 1i lin_labelle d 
somatostatin a alogue 
Tissue In-octreotide In-RC In-RC In-RC 
24 h 24 h 48 h 72h 
Adrenals 2.2 -+0.4 7.1 +2.6 0.87 -+0.12 
Pancreas 0.92 +0.08 0.97 -+0.28 0.42 +0.14 
Tumours 0.20 -+0.02 0.69 -+0.12 0.21 _+0.08 
Pituitary 0.11 +0.02 0.35 +0.02 0.11 +0.02 
Brain cortex 0.0011+0.0001 0.011+0.001 0.0015_+0.0002 
Kidneys 2.9 _+0.3 5.3 _+0.8 12 +1 
Liver 0.031 +0.006 0.74 +0.04 0.22 -+0.03 
Spleen 0.033 +0.018 0.93 -+0.08 0.36 _+0.08 
Intestines 0.05 _+0.01 0.37 _+0.09 0.12 _+0.03 
Soft tissue 0.0022_+0.0003 0.046_+0.003 0.011 _+0.004 
Blood 0.0035+0.0006 0.16 _+0.02 0.0067+0.0006 
In toto 13 +2 50 ___4 51 _+5 
Tumours vs 97 -+9 12 _+3 25 _+9 
soft tissue 
Tumours vs 58 _+9 3.6 _+0.8 32 _+8 
blood 
331 
0.73 _+ 0.03 
0.46 _+ 0.14 
0.20 _+ 0.08 
0.13 + 0.01 
0.0016+ 0.0002 
12 + 2 
0.26 -+ 0.07 
0.30 + 0.04 
0.18 -+ 0.04 
0.013 _+ 0.001 
0.0061_+ 0.0012 
49 -+ 2 
13 + 7 
30 _+11 
In-RC, [H IIn-DTPA-D-Phel]RC- 160; In-octreotide, [mIn-DTPA-D-Phel]octreotide 
Table 2. Specific binding in somatostatin 
receptor-positive organs and tumours 
(percentage injected ose per gram tissue, 
mean -+ SD) in tumour-bearing rats (n _> 4), 
at indicated time intervals after intravenous 
administration of0.5 ~g of lllIn-labelled 
somatostatin a alogue 
Tissue In-RC In-RC In-octreotide In-octreotide 
4h 24h 4h 24h 
Adrenals 5.0 _+0.3 6.1 +2.6 2.1 +0.5 1.8 +0.4 
Pancreas 0.44-+0.22 0.56+0.28 0.47+0.20 0.44_+0.15 
Tumours 0.30-+0.14 0.35_+0.12 0.21 -+0.09 0.19+0.05 
Pituitary 0.40+0.05 0.23_+0.02 0.16-+0.06 0.12-+0.02 
Brain cortex <0.001 <0.001 <0.001 <0.001 
Except for the brain cortex, all organs and tumours had specific binding significantly 
different from zero, P < 0.05 
In-RC, [H~In-DTPA-D-Phe~]RC-160; In-octreotide, [mIn-DTPA-D-Phel]octreotide 
D-Phe~]RC-160 are shown in Table 1. Between 24 and 
48 h after injection of [mln-DTPA-D-Phet]RC-160 there 
was a decrease of radioactivity in most tissues, accompa- 
nied by an increase of radioactivity in rat kidney. The 
uptakes in the kidney, in the somatostatin receptor-posi- 
tive tissues and in the tumour were higher for [HIIn-DT- 
PA-D-Phel]RC-160 than for[111In-DTPA-D-Phe~]octreo- 
tide. The ratios of tumour over blood and tumour over 
soft tissue for [1HIn-DTPA-D-Phe~]RC- 160 were signifi- 
cantly lower than those found for [I"In-DTPA-D- 
Phe~]octreotide, mainly because of the very low uptake 
of radioactivity in soft tissue after injection of [IHIn-DT- 
PA-D-PheJ]octreotide (Table 1). Table 1 also shows that 
even 72 h after injection of [mln-DTPA-D-Phel]RC-160 
the remaining radioactivity in blood is still twice the val- 
ue 24 h after injection of [1HIn-DTPA-D-Phe~]octreotide, 
0.0061% vs 0.0035% injected dose per gram. For soft 
tissue the relative difference is even higher, 0.013% vs 
0.002% injected dose per gra m (Table 1). 
Despite the decrease in radioactivity in most soma- 
tostatin receptor-negative tissues, i.e. in the majority of 
tissues, total body radioactivity does not decrease be- 
tween 24 and 48 h after the injection of [11tln-DTPA-D- 
Phel]RC-160, due to an increase of radioactivity in the 
kidneys (Table 1). This results in a significantly higher 
body retention of radioactivity after injection of [~11In- 
DTPA-D-Phel]RC-160 than with [111In-DTPA-D- 
Phel]octreotide. This higher concentration of radioactivi- 
ty in the kidneys after [H~In-DTPA-D-Phe~]RC-160 is 
striking, since renal excretion is also the predominant 
route for clearance of [~'In-DTPA-D-Phe~]octreotide. 
For instance about 50% of injected [1HIn-DTPA-D- 
Phel]octreotide is excreted via the kidneys in the first 30 
min after injection, as described previously by Bakker et 
al. [13]. 
In Table 2 the specific binding at several time inter- 
vals after injection of [11qn-DTPA-D-Phel]RC-160 and 
[11qn-DTPA-D-Phe~]octreotide is given for the somatos- 
tatin receptor-positive tissues and tumour. There were no 
significant differences in binding of either peptide to 
these sites. Also, no specific binding of either analogue 
was found in the brain, suggesting that they were unable 
to pass the blood-brain barrier. 
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Fig. 4a,bo Static posterior images in rats with unilateral implanted 
somatostatin receptor-positive CA20948 tumour, located at the 
upper part of the right hind leg, 24 h after injection f [mIn-DT- 
PA-D-Phe~]RC-160. Note the normal uptake of radioactivity in 
liver and kidneys in both images. There is accumulation of radio- 
activity in the tumour (a, no preteatment); note the absence of 
accumulation fradioactivity in the tumour in b. In b the rat was 
pretreated s.c. with 1 mg RC-160 45 rain prior to the injection 
with [mln-DTPA-D-Phe~]RC-160 in order to saturate the soma- 
tostatin receptors 
Metabolism 
SEP-PAK C~8 columns were used for measurement of
peptide-bound radioactivity in blood and urine of four 
control rats at 4 h and 24 h after the injection of [I~Iln- 
DTPA-D-Phe~]RC-160. The percentages of peptide-bo- 
und radioactivity in blood were 23 _+ 2 at 4 h p.i. and 18 
_ 1 at 24 h p.i. HPLC analysis of the ethanol fractions of 
the SEP-PAK C18 columns of these blood samples con- 
firmed that more than 90% of this peptide-bound rain 
was intact [mIn-DTPA-D-Phe~]RC-160 and at 24 h p.i. 
this figure had dropped below 50%. The nature of the 
metabolites of both rain-labelled radiopharmaceuticals 
was not further investigated. The percentage of peptide- 
bound l~In in urine samples was 73 ___ 4 at 4 h and 75 _+ 
2 at 24 h after injection of [mIn-DTPA-D-Phe~]RC-160. 
In the urine samples from two control rats 24 h after in- 
jection of [~Z1In-DTPA-D-PheZ]octreotide, when most of 
the radioactivity had already been excreted, more than 
90% of the rain was not peptide-bound, as described 
previously by Bakker et al. (t3). 
Imaging 
Dynamic images during the first 20 rain after injection 
of [mln-DTPA-D-Phe~]RC-160 or [nlIn-DTPA-D- 
Phe~]octreotide showed a rapid distribution of radioac- 
tivity over the whole body. Pretreatment with excess un- 
labelled RC-160 or octreotide did not affect the blood 
clearance. Immediately after injection of [mIn-DTPA-D- 
PheI]RC-160 or [mIn-DTPA-D-Phel]octreotide, an in- 
creasing amount of radioactivity was measured over the 
tumours. 
From digital static images obtained 24, 48 and 72 h 
after injection of [~In-DTPA-D-Phe~]RC-160, whole- 
body retention was found to be approximately 50% of 
the injected dose after 48 h and 72 h, and this retention 
was predominantly accounted for by radioactivity in the 
kidneys (see also Table 1). Figure 4 presents tatic ana- 
log images of two rats with unilateral somatostatin re- 
ceptor-positive CA20948 tumours, 24 h after the injec- 
tion of [mIn-DTPA-D-Phel]RC-160. Accumulation of 
radioactivity in the tumour and kidneys was observed. 
The uptake of radioactivity by the tumour was success- 
fully inhibited by the pretreatment of unlabelled RC-160 
(Fig. 4). 
Discussion 
Like octreotide, RC-160 is a somatostatin analogue with 
potent hormone secretion-inhibitory and antiproliferative 
characteristics in vivo and in vitro. However, discrepan- 
cies with octreotide have been described with regard to 
binding to a number of human cancers, such as breast, 
ovarian, exocrine pancreas, prostate, and colon carcino- 
mas [21-23]. Because radiolabelled RC-160 could have 
advantages over radiolabelled octreotide for the in vivo 
detection of some of these somatostatin receptor-positive 
tumours, at first we evaluated radioiodinated RC-160 as 
a radiopharmaceutical. These studies revealed some ma- 
jor drawbacks of 123I-RC-160 as compared to [123I- 
Tyr3]octreotide. The main disadvantage of ~23I-RC-160 
was its relatively low tumour to background ratio, im- 
plying poorer in vivo tumour detection [30]. In analogy 
with the development of [mIn-DTPA-D-Phel]octreotide 
we therefore evaluated [~In-DTPA-D-Phe~]RC - 160. 
Since for use in animal models no somatostatin receptor- 
positive tumours are available displaying binding speci- 
ficity for RC-160 and not for octreotide, we investigated 
both somatostatin analogues in the CA20948 tumour 
model. 
The radiolabelling of [DTPA-D-Phel]RC-160 with 
(high-quality) ~ltIn is a simple single-step procedure 
with a high efficiency of labelling (> 95%) and does not 
require special skills or equipment. We found no signifi- 
cant differences in biological activity between [~SIn-DT- 
PA-D-Phel]RC-160 and [l~SIn-DTPA-D-Phel]octreotide 
and the two non-labelled [DTPA-D-Phel]-somatostatin 
analogues, as measured by inhibition of rat growth hor- 
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mone secretion. Recently, however, we found that the 
non-DTPA-conjugated RC-160 was significantly more 
potent in inhibiting hormone release by normal and tu- 
mourous pituitary cells [37]. Therefore, a direct compar- 
ison between somatostatin analogues with their DTPA- 
conjugated counterparts should be made with care. The 
results in the binding studies demonstrated that both 
non-labelled [DTPA-D-Phel]-somatostatin analogues are 
high-affinity and selective ligands for the somatostatin 
receptor. This was also demonstrated in the in vivo ex- 
periments after injection of [~lIn-DTPA-D-Phel]octreo- 
tide and [H1In-DTPA-D-Phel]RC-160, in which uptake 
and specific binding in somatostatin receptor-positive 
tissues and tumours were found. Also, the somatostatin 
receptor-positive tumours were clearly visualized by 
gamma camera scintigraphy. However, we did find dif- 
ferences in metabolism and clearance of radioactivity 
from the blood compartment, soft tissue and other soma- 
tostatin receptor-negative tissues. A higher radioactivity 
concentration and a slower clearance from these tissues 
were demonstrated for [11qn-DTPA-D-Phel]RC-160. 
The difference in uptake of radioactivity in the liver and 
excretion in the intestines after injection of [mIn-DTPA- 
D-Phel]RC-160 or [mIn-DTPA-D-Phel]octreotide was 
probably due to a difference in handling of the two ana- 
logues by the liver [38]. In the perfused rat liver uptake 
of radioactivity from the medium was 20% of the dose 
in the liver during the first hour of perfusion with [111In- 
DTPA-D-Phel]RC-160, but 2% of the dose for [11qn- 
DTPA-D-Phel]octreotide. Less than 1% of the dose of 
both radiolabelled somatostatin analogues was excreted 
in the bile, where they were in the peptide-bound form. 
The presence of the C-terminal amino acid trypto- 
phan in RC-160 (see Fig. 1) enhances the lipophilicity of 
the molecule, and this may explain the enhanced uptake 
of [mIn-DTPA-D-Phel]RC-160 and/or its metabolites in
the liver and its reduced clearance from tissues and 
blood. The ratios of tumour over blood and tumour over 
soft tissue for [11qn-DTPA-D-Phel]RC-160 are lower 
than those for [mIn-DTPA-D-Phel]octreotide. Although 
the uptake of radioactivity in the tumour after [~HIn-DT- 
PA-D-Phel]RC-160 experiments i higher, the clearance 
of radioactivity from the blood compartment and soft tis- 
sue is much slower than for [1HIn-DTPA-D-Phel]octreo- 
tide. This implies a poorer visualization of tumours 
when the former somatostatin analogue is used. The lack 
of uptake in brain cortex suggests inability of both [DT- 
PA-D-Phe~]-somatostatin analogues to penetrate an in- 
tact blood-brain barrier. This contrasts with earlier data 
on RC-160 and radioiodinated RC-160 [28-30] and im- 
plies that [mIn-DTPA-D-Phel]RC-160 is most probably 
not suitable for visualizing human brain tumours with an 
intact blood-brain barrier. However, because mention has 
been made of somatostatin receptor-positive tumours 
with other subtypes which do not bind (labelled) octreo- 
tide, we want to hypothesize that [~llln-DTPA-D- 
Phel]RC-160 might be applicable in the field of nuclear 
medicine in the visualization of some human cancers. 
We currently investigate patients with a negative [HlIn- 
DTPA-D-Phel]octreotide gamma camera scintigraphy 
who have tumours which do not bind octreotide, but be- 
long to the group of tumours which Schally et al. sug- 
gested to have a high affinity for RC-160 [21-23]. The 
therapeutic possibilities of [~3q-Tyr3]octreotide are low 
[7], since the residence time of 131I in the tumour is 
short. This is because radioiodinated [Tyr3]octreotide is 
rapidly metabolized with release of 131I in the circula- 
tion, as has been demonstrated previously in rats [6, 30] 
and patients [7]. 
Since the residence time in/on the tumour cells of 
somatostatin analogues with a DTPA group appears pro- 
longed, it seems worthwhile to investigate whether DT- 
PA peptides labelled with L31I or other 13-emitting radio- 
nuclides would be suitable for radiotherapy. Therefore, 
[131I-TyrB][DTPA-D-Phel]octreotide or [131I-TyrB][DTPA- 
D-Phel]RC-160 could open new therapeutic applications 
for patients bearing somatostatin receptor-positive tu- 
mours. However, whether the residence time of the radi- 
oiodinated somatostatin analogues with a DTPA group is 
also prolonged needs to be established, since deiodina- 
tion of the molecule will then hamper the therapeutic ap- 
plication. 
In conclusion, [mln-DTPA-D-Phel]RC-160 does not 
seem to have advantages over [mln-DTPA-D-Phe~]oc- 
treotide as a radiopharmaceutical for somatostatin recep- 
tor scintigraphy, despite the fact that [HIln-DTPA-D- 
Phel]RC -160 shows specific high-affinity binding to var- 
ious somatostatin receptor-positive organs. In contrast to 
radioiodinated [Tyr3]RC -160 and RC- 160, which do pass 
the blood-brain barrier, our experiments show that [mln- 
DTPA-D-Phel]RC-160 and [l~qn-DTPA-D-Phe~]octreo- 
tide do not pass the blood-brain barrier. In comparison 
with [mln-DTPA-D-Phel]octreotide th  main disadvan- 
tage of [11qn-DTPA-D-Phe~]RC-160 (aswe recently also 
showed for 123I-RC-160) is its relatively low tumour to 
blood (background) ratio, implying poorer in vivo tu- 
mour detection. However, previous studies suggest hat 
RC-160 might bind to several human cancer types which 
do not bind octreotride. If the existence of different som- 
atostatin receptor subtypes i  confirmed, RC-160 and, in 
spite of its disadvantages, [mln-DTPA-D-Phel]RC-160 
may open new diagnostic and/or therapeutic applications 
for patients bearing such tumours. Further studies in pa- 
tients need to be performed, with special attention to pa- 
tients with a negative [11qn-DTPA-D-Phel]octreotide 
gamma camera scintigraphy scan and/or patients with 
tumours with a higher affinity for RC-160. Since the 
DTPA group appears to prolong the residence time of 
somatostatin analogues in/on the tumour cells, it seems 
worthwhile to investigate whether DTPA peptides la- 
belled with 1311 or other p-emitting radionuclides would 
be suitable for radiotherapy. Consequently, [1311- 
Tyr 3][DTPA-D-Phel]OctreOtide or [131I-Tyr3][DTPA-D- 
Phel]RC-160 could open new therapeutic applications 
for patients bearing somatostatin receptor-positive tu- 
mours. 
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